Proven to perform

SMART Trial

3-year results



Medtronic

Clinical valve thrombosis is a signal of longer-term complexities you can't ignore.[1]

6x more clinical valve thrombosis†

with SAPIEN TAVI

through 3 years in small annulus patients.‡,[2]

p=0.0084



† Clinical prosthetic valve thrombosis as defined by VARC-3.

‡ In patients with small annuli (area ≤ 430 mm2) in all-comers trial, consisting of majority low surgical risk participants (52.1%).

1. Chitturi KR, Aladin AI, Braun R, et al. Bioprosthetic Aortic Valve Thrombosis: Definitions, Clinical Impact, and Management: A State-of-the-Art Review. Circ Cardiovasc Interv. 2024;17(7):e014143. doi:10.1161/CIRCINTERVENTIONS.123.014143
2. Herrmann H. Three-Year Outcomes of the SMART Trial. Presented at EuroPCR; Paris, France, May 20, 2026.

Prosthesis-patient mismatch (PPM) increases mortality risks.

Patients with ≥ moderate PPM experienced 2.24 higher cardiovascular mortality risk in SMART Trial through three years compared to patients without PPM (p = 0.014).[◊,¶,1]

3.4x more ≥ moderate PPM

with SAPIEN TAVI

at 30 days in small annulus patients.[‡,#,1]

p < 0.001



◊ Adjusted for age, sex, COPD status, renal function (GFR < 60mL/min/1.73 m^2), LVEF, and stroke volume index (SVI).

¶ Mortality was landmarked at the reference echo (30-day echo if available, otherwise discharge echo).

‡ In patients with small annuli (area ≤ 430 mm^2) in all-comers trial of 716 patients, consisting of majority low surgical risk participants (52.1%)

Reference echo (30-day if available, otherwise discharge echo). PPM as defined by VARC-3.

1. Herrmann H. Three-Year Outcomes of the SMART Trial. Presented at EuroPCR; Paris, France, May 20, 2026.

More than 1 in 2 patients‡

are expected to experience BVD§ with SAPIEN TAVI

within 3 years[1] p < 0.001

Three years. Still superior.

3x less BVD§ with Evolut™ compared with SAPIEN™* TAVI

Durable valve performance, as defined by freedom from bioprosthetic valve dysfunction (BVD), is critical, regardless of the procedure or platform.

Sustained **excellent patient outcomes** through 3 years.[1]

Clinical outcome composite:
All-cause mortality, disabling stroke, or heart failure rehospitalization.

Evolut™ TAVI: 25.4%
SAPIEN™* TAVI: 22.6%
Log-rank P-value: 0.44
Hazard ratio, 1.13
(95% CI, 0.83 to 1.53)

‡ In patients with small annuli (area ≤ 430 mm2) in all-comers trial, consisting of majority low surgical risk participants (52.1%).

§ Valve performance as defined as freedom from bioprosthetic valve dysfunction (BVD) through 36 months. BVD is defined as a composite including any of the following: hemodynamic structural valve dysfunction (mean gradient ≥ 20 mmHg), non-structural valve dysfunction (severe prothesis-patient mismatch or ≥ moderate aortic regurgitation), clinical thrombosis, endocarditis, and aortic valve reintervention.

1. Herrmann H. Three-Year Outcomes of the SMART Trial. Presented at EuroPCR; Paris, France, May 20, 2026.

Through three years,

Evolut™ TAVI maintains superior valve performance† vs. SAPIEN™* TAVI in small annulus patients.‡,[1]



† Valve performance as defined as freedom from bioprosthetic valve dysfunction (BVD) through 36 months. BVD is defined as a composite including any of the following: hemodynamic structural valve dysfunction (mean gradient ≥ 20 mmHg), non-structural valve dysfunction (severe prothesis-patient mismatch or ≥ moderate aortic regurgitation), clinical thrombosis, endocarditis, and aortic valve reintervention.

‡ In patients with small annuli (area ≤ 430 mm2) in all-comers trial, consisting of majority low surgical risk participants (52.1%).

1. Herrmann H. Three-Year Outcomes of the SMART Trial. Presented at EuroPCR; Paris, France, May 20, 2026.

This material should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s).

Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the (implant) procedure, indications, contraindications, warnings, precautions, and potential adverse events. For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI. If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser. Medtronic products placed on European markets comply with EU and UK legislation (if applicable) on medical devices. For any further information, contact your local Medtronic representative and/or consult Medtronic's websites.

Medtronic medical devices in compliance with the Spanish legislation in force.

Medtronic

Medtronic International Trading Sàrl
Route du Molliau 31
Case postale
1131 Tolochenaz
Switzerland
Tel: +41 (0) 21 802 70 00
Fax: +41 (0) 21 802 79 00

medtronic.eu

CE-CV-2600168 v1.0
05/2026